Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Cancer, Cancer, Dental |
Therapuetic Areas: | Dental / Maxillofacial Surgery, Oncology |
Healthy: | No |
Age Range: | 20 - 85 |
Updated: | 2/1/2018 |
Start Date: | August 2012 |
End Date: | August 2018 |
Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients
This study will evaluate the ability of grape exosomes, given to the subject as grape powder,
as an important anti-inflammatory agent to reduce the incidence of oral mucositis during
radiation and chemotherapy treatment for head and neck tumors.
as an important anti-inflammatory agent to reduce the incidence of oral mucositis during
radiation and chemotherapy treatment for head and neck tumors.
The purpose of this study is to investigate the ability of plant (grape) exosomes to prevent
oral mucositis associated with chemoradiation treatment of head and neck cancer. Also, to be
evaluated is the effect of grape exosomes on the production of cytokines and immune responses
to tumor exosomal antigens, metabolic and molecular markers in these patients.
oral mucositis associated with chemoradiation treatment of head and neck cancer. Also, to be
evaluated is the effect of grape exosomes on the production of cytokines and immune responses
to tumor exosomal antigens, metabolic and molecular markers in these patients.
Inclusion Criteria:
- Patients must have definitive diagnosis of head and neck cancer.
- Concurrent chemoradiation treatment of the primary tumor must be an option for the
newly diagnosed cancer.
- Patients must be informed of the investigational nature of this study and sign and
give written informed consent in accordance with institutional and federal guidelines.
- Absence of life limiting medical conditions
- Ability to understand and willingness to sign a written informed consent document.
- ECOG performance status 0, 1, or 2 (Karnofsky > 60%).
- Patients must have adequate bone marrow function. ANC > 1000/microL and Platelet count
>100,000/microL
- Age >20 years
Exclusion Criteria:
- Known familial head and neck cancer syndrome
- Pregnancy
- Known HIV
- Patients receiving immunosuppressive drugs
- Inflammatory bowel disease
- Active second malignancy in the last 5 years
- Patients receiving any other investigational agent(s)
- Patients who have received any prior chemotherapy or radiation therapy to the primary
head and neck cancer
We found this trial at
1
site
529 S Jackson St
Louisville, Kentucky 40202
Louisville, Kentucky 40202
(502) 562-4369
Phone: 502-562-3429
James Graham Brown Cancer Center No one should feel compelled to leave Kentucky to seek...
Click here to add this to my saved trials